The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
Open accessAbstract
Fabry disease is an X-linked lysosomal storage disease caused by deficiency of α-galactosidase A that affects males and shows disease expression in heterozygotes. The characteristic progressive renal insufficiency, cardiac involvement, and neuropathology usually are ascribed to globotriaosylceramide accumulation in the endothelium. However, no direct correlation exists between lipid storage and clinical manifestations, and treatment of patients with recombinant enzymes does not reverse several key signs despite clearance of lipid from the endothelium. We therefore investigated the possibility that globotriaosylceramide metabolites are a missing link in the pathogenesis. We report that deacylated globotriaosylceramide, globotriaosylsphingosine, and a minor additional metabolite are dramatically increased in plasma of classically affected male Fabry patients and plasma and tissues of Fabry mice. Plasma globotriaosylceramide levels are reduced by therapy. We show that globotriaosylsphingosine is an inhibitor of α-galactosidase A activity. Furthermore, exposure of smooth muscle cells, but not fibroblasts, to globotriaosylsphingosine at concentrations observed in plasma of patients promotes proliferation. The increased intima-media thickness in Fabry patients therefore may be related to the presence of this metabolite. Our findings suggest that measurement of circulating globotriaosylsphingosine will be useful to monitor Fabry disease and may contribute to a better understanding of the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Self-citationEnzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Self-citationSeparation of plasma lipoproteins by density-gradient ultracentrifugation
Redgrave, T. G., Roberts, D. C. K., & West, C. E. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90488-1 · Cited by 1,107
Enzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053
Self-citationα-Galactosidase A deficiency. Fabry disease
Desnick, R. J. (2001) · Cited by 605
SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
Ng, M., Uffon, N. A. G., Ilcox, W. I. R. W., Ermain, P. G., Ee, P., Aldek, S. T. W., Aplan, L. O. C., Inthorst, E. L., & Esnick, R. O. J. D. (2001) · Cited by 482
Fabry's Disease: Alpha-Galactosidase Deficiency
Kint, J. A. (1970) · Science · doi:10.1126/science.167.3922.1268 · Cited by 470
α-Galactosidase A deficient mice: A model of Fabry disease
Ohshima, T., Murray, G. J., Swaim, W. D., Longenecker, G., Quirk, J. M., Cardarelli, C. O., Sugimoto, Y., Pastan, I., Gottesman, M. M., Brady, R. O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2540 · Cited by 367
Self-citationKrabbe disease: a galactosylsphingosine (psychosine) lipidosis.
Svennerholm, L., Vanier, M. T., & Månsson, J. E. (1980) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39839-4 · Cited by 327
Brady, R. O., Tallman, J. F., Johnson, W. G., Gal, A. E., Leahy, W. R., Quirk, J. M., & Dekaban, A. S. (1973) · New England Journal of Medicine · doi:10.1056/nejm197307052890103 · Cited by 312
Self-citationNatural history of Fabry disease in females in the Fabry Outcome Survey
Deegan, P. B., Baehner, A. F., Barba Romero, M.-Á., Hughes, D. A., Kampmann, C., & Beck, M. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036327 · Cited by 304
Nilsson, O., & Svennerholm, L. T. (1982) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1982.tb07950.x · Cited by 283
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
Linthorst, G. E., Hollak, C. E. M., Donker-Koopman, W. E., Strijland, A., & Aerts, J. M. F. G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00924.x · Cited by 282
Self-citationSuzuki, K. (1998) · Neurochemical Research · doi:10.1023/a:1022436928925 · Cited by 281
Anderson–Fabry disease: Clinical manifestations of disease in female heterozygotes
Whybra, C., Kampmann, C., Willers, I., Davies, J., Winchester, B., Kriegsmann, J., Brühl, K., Gal, A., Bunge, S., & Beck, M. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1012993305223 · Cited by 276
Progressive Accumulation of Toxic Metabolite in a Genetic Leukodystrophy
Igisu, H., & Suzuki, K. (1984) · Science · doi:10.1126/science.6719111 · Cited by 236
Orvisky, E., Park, J. K., LaMarca, M. E., Ginns, E. I., Martin, B. M., Tayebi, N., & Sidransky, E. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00117-8 · Cited by 193
Vedder, A. C., Linthorst, G. E., Houge, G., Groener, J. E. M., Ormel, E. E., Bouma, B. J., Aerts, J. M. F. G., Hirth, A., & Hollak, C. E. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000598 · Cited by 192
Self-citationThe Enzymatic Synthesis of Psychosine
Cleland, W. W., & Kennedy, E. P. (1960) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69582-1 · Cited by 180
The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels
Vedder, A. C., Linthorst, G. E., van Breemen, M. J., Groener, J. E. M., Bemelman, F. J., Strijland, A., Mannens, M. M. A. M., Aerts, J. M. F. G., & Hollak, C. E. M. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0484-8 · Cited by 180
Self-citationLockman, K., Hinson, J. S., Medlin, M. D., Morris, D. R., Taylor, J. M., & Mack, C. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405432200 · Cited by 153
Gupta, S. N., Ries, M., Kotsopoulos, S., & Schiffmann, R. (2005) · Medicine · doi:10.1097/01.md.0000178976.62537.6b · Cited by 122
Groener, J. E. M., Poorthuis, B. J. H. M., Kuiper, S., Helmond, M. T. J., Hollak, C. E. M., & Aerts, J. M. F. G. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.079012 · Cited by 116
Self-citationCardiac and Vascular Hypertrophy in Fabry Disease
Barbey, F., Brakch, N., Linhart, A., Rosenblatt‐Velin, N., Jeanrenaud, X., Qanadli, S. D., Steinmann, B. U., Burnier, M., Paleček, T., Bultas, J., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000209649.60409.38 · Cited by 115
Cellular and tissue localization of globotriaosylceramide in Fabry disease
Askari, H., Kaneski, C. R., Semino‐Mora, C., Desai, P., Ang, A. L., Kleiner, D. E., Perlee, L. T., Quezado, M., Spollen, L. E., Wustman, B. A., et al. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0468-6 · Cited by 113
Manifestations of Fabry disease in placental tissue
Vedder, A. C., Strijland, A., Weerman, M. A. V. B., et al. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0196-0 · Cited by 111
Self-citationSchueler, U., Kolter, T., Kaneski, C. R., Blusztajn, J. K., Herkenham, M. A., Sandhoff, K., & Brady, R. O. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.016 · Cited by 96
Self-citationMonitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide
Whitfield, P. D., Calvin, J., Hogg, S. L., O'Driscoll, E., Halsall, D., Burling, K., Maguire, G., Wright, N., Cox, T. M., Meikle, P. J., et al. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-4415-x · Cited by 90
Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA
Blom, D., Speijer, D., Linthorst, G., Donker-Koopman, W. G., Strijland, A., & Aerts, M. F. G. J. (2003) · The American Journal of Human Genetics · doi:10.1086/345309 · Cited by 61
Self-citationStructural and functional changes in peripheral vasculature of Fabry patients
Kalliokoski, R., Kalliokoski, K. K., Penttinen, M. T., Kantola, I. M., Leino, A. E., Viikari, J. S. A., Simell, O., Nuutila, P., & Raitakari, O. T. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0340-x · Cited by 60
Barbey, F., Brakch, N., Linhart, A., Jeanrenaud, X., Palecek, T., Bultas, J., Burnier, M., & Hayoz, D. (2006) · Acta Paediatrica · doi:10.1080/08035320600618924 · Cited by 54
Ohashi, T., Sakuma, M., Kitagawa, T., Suzuki, K., Ishige, N., & Eto, Y. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.06.013 · Cited by 53
Accumulation of Lysosphingolipids in Tissues from Patients with GM1 and GM2 Gangliosidoses
Kobayashi, T., Goto, I., Okada, S., Orii, T., Ohno, K., & Nakano, T. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08460.x · Cited by 46
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Lysosomal disorders: From storage to cellular damage
Ballabio, A., & Gieselmann, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.12.001 · Cited by 571
Automated Chemical Oligosaccharide Synthesis: Novel Approach to Traditional Challenges
Panza, M., Pistorio, S. G., Stine, K. J., & Demchenko, A. V. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00051 · Cited by 343
Metadata
- Authors
- Aerts, J. M., Groener, J. E., Kuiper, S., Donker-Koopman, W. E., Strijland, A., Ottenhoff, R., van Roomen, C., Mirzaian, M., Wijburg, F. A., Linthorst, G. E., Vedder, A. C., Rombach, S. M., Cox-Brinkman, J., Somerharju, P., Boot, R. G., Hollak, C. E., Brady, R. O., & Poorthuis, B. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-02-26
- Volume
- 105
- Issue
- 8
- Pages
- 2812-2817
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2097776291
- Cited by
- 731
- References
- 35
- FWCI
- 20.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.